Market Overview

Marina Biotech, Tekmira Enter Worldwide Non-Exclusive Licensing Agreement for Nucleic Acid Chemisty

Related TKMR
Tekmira Officially Becomes Arbutus Biopharma
5 Biotech Stocks On Deck With The FDA

Marina Biotech, Inc. announced today that it has entered into a license agreement with Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), where Marina will provide Tekmira a worldwide, non-exclusive license to Marina Biotech's Unlocked Nucleobase Analog (UNA) technology for the development of RNA interference therapeutics. Tekmira will have full responsibility for the development and commercialization of any products arising under the Agreement. Under terms of the Agreement, Marina Biotech will receive an upfront payment plus milestone and royalty payments on products developed by Tekmira that use UNA technology. Further terms of the Agreement were not disclosed.

Posted-In: News


Related Articles (TKMR)

View Comments and Join the Discussion!

Partner Center